Fenómeno de Raynaud
Palavras-chave:
Raynaud, Esclerose Sistémica, CapilaroscopiaResumo
O fenómeno de Raynaud (FR) caracteriza-se por episódios
reversíveis de vasoespasmo das extremidades, associados a
palidez, seguidos por cianose e rubor, que ocorrem, geralmente,
após exposição ao frio ou stress. Pode originar complicações
graves como a ulceração, necrose e gangrena, resultando em
amputação digital.
O FR pode ser primário quando não está associado a nenhuma
doença ou condição, ou secundário. A sua correcta orientação clínica é fundamental uma vez que, em muitos casos, pode tratar-se
do primeiro sinal de uma doença subjacente grave. Nos últimos
anos, os avanços no estudo da sua fisiopatologia permitiram o
aparecimento de novas opções terapêuticas.
Neste artigo pretendemos rever a sua patogénese, orientação
clínica e tratamentos disponíveis.
Downloads
Referências
Wigley FM. Clinical pratice. Raynaud´s phenomenon. N Engl J Med 2002; 347: 1001-1008.
Voulgari P, Alamanos Y, Papazisi D, Christou K, Papanikolaou C, Drosos A. Prevalence of Raynauds phenomenon in a healthy Greek population. Ann Rheum Dis 2002; 59: 206-210.
Urbano F. Raynauds phenomenon. Hospital physician 2001; 27-30.
Kayser C, Correa M, Andrade L. Fenomeno de Raynaud. Rev Bras Reumatol 2009; 49 (1): 48-63.
Wigley FM, Flavahan NA. Raynaud´s phenomenon. Rheum Dis Clin North Am 1996; 22: 765-781.
Maricq HR, Carpentier PH,Weinrich MC et al.Geographic variation in the prevalence of Raynaud´s phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France. J Rheumatol 1993; 20:70-76.
Harada N, Ueda A, Takegata S. Prevalence of Raynaud´s phenomenon in Japanese males and females. J Clin Epidemiol 1991;44:649-655.
Kaminski M, Bourgine M, Zins M, Touranchet A, Verger C. Risk factors of Raynaud´s phenomenon among workers in poultry slaughterhouses and canning factories. Int J Epidemiol 1997;26:371-380.
Bartelink ML, Wollersheim H, Van de Lisdonk E, Thien T. Raynaud´s phenomenon: subjective influence of female sex hormones. Int Angiol 1992;11:309-315.
Valter I, Maricq HR. Prevalence of Raynaud phenomenon in Tartu and Tartumaa, southern Estonia. Scand J Rheumatol 1997;26:117-124.
Di Giacomo RA, Kremer JM, Shah DM. Fish oil supplementation in patients with Raynauds phenomenon: A double-blind controlled prospective study. Am J Med 1989;86:158.
Silva I, Loureiro T, Almeida I, Mansilha A, Almeida R, Vasconcelos C. Fenomeno de Raynaud. Angiologia e Cirurgia Vascular 2011; 7: 13-20.
Herrick AL. Pathogenesis of Raynauds phenomenon. Rheumatology 2005;44:587-596.
Flavahan NA, Flavahan S, Mitra S, Chotani MA. The vasculopathy of Raynauds phenomenon and scleroderma. Rheum Dis Clin North Am 2003; 29:275-291.
Schachna L, Wigley FM. Targeting mediators of vascular injury in scleroderma.
Curr Opin Rheumatol 2002; 14:686-693
Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum 1975; 4:351-368.
Suderkötter C, Riemekasten G. Pathophysiology and clinical consequences of Raynauds phenomenon related to systemic sclerosis. Rheumatology 2006;45(S3): 33-35.
Wigley FM. Clinical manifestations and diagnosis of the Raynaud phenomenon. In UptoDate, Jan 2012.
Planchon B, Pistorius MA, Beurrier P, De Faucal P. Primary Raynaud´s phenomenon: age of onset and pathogenesis in a prospective study of 424 patients. Angiology 1994; 45:677-686.
Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 1998; 158:595.
Hirschl M, Hirschl K, Lenz M, et al. Transition from primary Raynaud´s phenomenon to secondary Raynaud´s phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthritis Rheum 2006; 54:1974.
Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004 140:37-50.
Wollersheim H, Thien T, Hoet MH, Van Venrooy WJ. The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon. Eur J Clin Invest 1989; 19:535.
Ingegnoli F, Boracchi P, Gualtierotti R et al. Prognostic model based on nailfold capillaroscopy for identifying Raynaud´s phenomenon patients at high risk for the development of a scleroderma spectrum disorder. Arthr & Rheumat 2008; 58: 2174-2182.
Cutolo M, Grassi W, Cerinic M. Raynaud´s phenomenon and the role of capillaroscopy. Arthr & Rheumat 2003; 48: 3023-3030.
Wigley FM. Nonpharmacologic therapy for the Raynaud phenomenon. In UptoDate, Jan 2012.
Wigley FM. Pharmacological and surgical treatment of the Raynaud phenomenon. In UptoDate, Jan 2012.
Coleiro B, Marshall S, Denton C. Treatment of the Raynaud´s phenomenon with the selective serotonine reuptake inhibitor fluoxetine. Rheumatology 2001; 40: 1038-1043.
Herrick AL Diagnosis and management of scleroderma peripheral vascular disease. Rheum Dis Clin North Am 2008; 34:89-114.
Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896.
Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50:3985.
Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud´s phenomenon and digital ulcers. J Rheumatol 2008; 35:1801.33.
Kuwana M, Okazaki Y, Kaburaki J. Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis. Mod Rheumatol 2009; 19:530
Ficheiros Adicionais
Publicado
Como Citar
Edição
Secção
Licença
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Direitos de Autor (c) 2023 Medicina Interna
Acesso livre
